SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies
Ikemura, N.; Hoshino, A.; Higuchi, Y.; Taminishi, S.; Inaba, T.; Matoba, S.
Show abstract
The novel SARS-CoV-2 variant, Omicron (B.1.1.529) contains about 30 mutations in the spike protein and the numerous mutations raise the concern of escape from vaccine, convalescent sera and therapeutic drugs. Here we analyze the alteration of their neutralizing titer with Omicron pseudovirus. Sera of 3 months after double BNT162b2 vaccination exhibite [~]27-fold lower neutralization titers against Omicron than D614G mutation. Neutralization titer is also reduced in convalescent sera from Alpha and Delta patients. However, some Delta patients have relatively preserved neutralization activity up to the level of 3-month double BNT162b2 vaccination. Omicron escapes from the cocktail of imdevimab and casirivimab, whereas sotrovimab that targets the conserved region to prevent viral escape is effective to Omicron similarly to the original SARS-CoV-2. The ACE2 decoy is another modality that neutralize the virus independently of mutational escape and Omicron is also sensitive to the engineered ACE2.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Rescue of SARS-CoV-2 from a single bacterial artificial chromosome 96%
- B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies 95%
- JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis 95%
Similar papers in this journal
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster 94%
- Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases 94%
- Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread 93%
Similar papers in this journal
Similar papers in this journal
- Cytoplasmic domain and enzymatic activity of ACE2 is not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells 95%
- Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch 93%
- Autographa californica Multiple Nucleopolyhedrovirus orf13 is Required for Efficient Nuclear Egress of Nucleocapsids 92%
Similar papers in this journal
- Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection 96%
- Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2 95%
- Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.